In a significant advancement for India's fight against antimicrobial resistance (AMR), Wockhardt Ltd has received a favorable recommendation from the Central Drugs Standard Control Organisation's (CDSCO) Subject Expert Committee (SEC) for its novel antibiotic Zaynich (zidebactam/cefepime, WCK 5222). This key regulatory nod, announced on March 30, 2026, positions Zaynich for final approval by the Drugs Controller General of India (DCGI), marking a potential game-changer in treating gram-negative bacterial infections prevalent in the country.

Zaynich represents India's first new chemical entity (NCE) antibiotic developed indigenously in nearly three decades, addressing a critical gap in therapies for extensively drug-resistant (XDR) pathogens. Developed over 15 years by a team of more than 150 scientists spanning 10 disciplines at Wockhardt's research facilities, the drug embodies the culmination of persistent innovation amid global AMR challenges.

The Mechanism Behind Zaynich's Power

Zaynich combines cefepime, a fourth-generation cephalosporin antibiotic, with zidebactam, a novel β-lactam enhancer. Traditional β-lactam antibiotics like cephalosporins are rendered ineffective by bacterial enzymes called β-lactamases and structural changes such as porin loss or efflux pumps in gram-negative bacteria. Zidebactam's dual action disrupts this: it inhibits key penicillin-binding proteins (PBPs, specifically PBP2 and PBP3) essential for bacterial cell wall synthesis while also neutralizing β-lactamases, including metallo-β-lactamases like NDM-1. This synergy restores cefepime's bactericidal potency against multidrug-resistant (MDR) and XDR strains.

The Clinical and Laboratory Standards Institute (CLSI) has assigned an investigational susceptible breakpoint of 64 mg/L for zidebactam/cefepime, signaling its broad coverage against priority pathogens identified by the World Health Organization (WHO) and U.S. Centers for Disease Control and Prevention (CDC), such as carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa, and carbapenem-resistant Enterobacterales (CRE).

In practical terms, this means Zaynich can penetrate bacterial outer membranes effectively, even in low-oxygen environments common in chronic infections, offering shorter treatment durations—typically 7-14 days intravenously—compared to prolonged regimens for resistant infections.

Robust Clinical Evidence from Indian Trials

A pivotal Phase II multicentre study across 15 leading tertiary care hospitals in India demonstrated Zaynich's superior performance. Involving patients with confirmed meropenem-resistant infections, the trial reported over 97% clinical efficacy at test-of-cure (7-10 days post-treatment). Breakdown: 100% success in bloodstream infections (BSI), hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP), and complicated intra-abdominal infections (cIAI); 97.3% in complicated urinary tract infections (cUTI).

These hospitals, often affiliated with premier medical colleges like those under AIIMS, PGIMER Chandigarh, and Christian Medical College (CMC) Vellore—a deemed university—highlight the real-world applicability in India's overburdened ICUs. More than 100 critically ill patients with XDR gram-negative infections were successfully treated, underscoring Zaynich's role in salvage therapy where alternatives failed.

Pathogens tackled included Acinetobacter spp. (common in CRAB), Pseudomonas aeruginosa (notorious for pneumonia in ventilated patients), Klebsiella pneumoniae, and Escherichia coli—strains driving India's AMR epidemic.

Global Phase III Success and Compassionate Use Data

Building on Indian data, a global Phase III trial enrolled 530 patients across 64 sites in the US, Europe, Latin America, China, and India for complicated UTI and acute pyelonephritis (cUTI/AP). Zaynich showed superiority over meropenem in combined clinical and microbiological cure rates, with 99.5% enrolment completed.

Additionally, compassionate use in 85 XDR cases across India, US, Malaysia, and France yielded strong efficacy, treating patients with no viable options. Case reports from King George's Medical University (KGMU) Lucknow—a prominent state university—and CMC Vellore detail successes in NDM-producing Pseudomonas aeruginosa sepsis and sino-pulmonary infections post-renal transplant.

These outcomes, published in journals like Annals of Clinical Microbiology and Antimicrobials, involved collaborations with university researchers such as Balaji Veeraraghavan from Dr. ALM Post Graduate Institute of Basic Medical Sciences (PGIBMS), affiliated with the University of Madras.

Photo by Karl Solano on Unsplash

India's Alarming AMR Landscape

Antimicrobial resistance imposes a staggering burden on India. In 2021, an estimated 267,000 deaths were directly attributable to AMR, with 987,000 associated, predominantly from gram-negative bacteria. Gram-negatives account for over 70% of hospital infections, with CRAB and CRE mortality rates exceeding 40-60% in ICUs. By 2050, projections warn of 10 million annual global AMR deaths, with India bearing a disproportionate share due to high infection rates, overuse of antibiotics, and dense population.

Superbugs like NDM-1 producers, first identified in India, exemplify the crisis. Nearly a million annual deaths from untreated resistant infections highlight the urgency. Zaynich's approval could avert thousands of deaths yearly, reducing hospital stays and costs—estimated at billions in economic loss.Explore IHME's detailed AMR burden report for India.

University-Led Research Fueling the Breakthrough

While Wockhardt spearheaded development, academic institutions played crucial roles. Over 100 publications on Zaynich feature Indian university experts. The Institute of Chemical Technology (ICT) Mumbai contributed to zidebactam's synthesis strategy. Researchers from PGIBMS Chennai and ICMR-National Institute of Cholera tested in vitro activity against carbapenem/colistin-resistant Klebsiella.

CMC Vellore documented salvage therapy successes, while KGMU Lucknow reported compassionate use in sepsis. These collaborations exemplify public-private partnerships vital for India's AMR research ecosystem. Universities like IITs and IISERs are also advancing AMR genomics and novel inhibitors, training the next generation of researchers through PhD programs and ICMR grants.

Such ties underscore higher education's pivot towards translational research, with initiatives like the Antimicrobial Resistance Research Society of India (AMRRSI) fostering multidisciplinary efforts.Learn more about AMRRSI's launch.

Regulatory Milestones and Global Ambitions

Beyond India, Zaynich's NDA was accepted by US FDA in December 2025 with Fast Track, Qualified Infectious Disease Product (QIDP), and priority review designations—first for an Indian NCE. EU Marketing Authorisation Application is advancing. Wockhardt eyes launches in US/EU by mid-2026, targeting a $7 billion market for resistant gram-negative therapies.

In India, post-DCGI nod, commercial rollout could begin soon, prioritizing ICUs. The drug's nine Phase I studies (US/China, ~300 subjects) confirmed safety.

Public Health Implications and Challenges Ahead

Zaynich could transform sepsis management, where gram-negatives cause 50% of cases in India. Shorter courses reduce resistance pressure, but stewardship programs are essential. Challenges include affordability, distribution to rural areas, and over-the-counter antibiotic misuse.

Government initiatives like the National Action Plan on AMR emphasize surveillance via ICMR networks, where universities contribute data. Integrating Zaynich into guidelines could save lives and cut healthcare costs by 20-30% for resistant infections.

Photo by Karl Solano on Unsplash

Future Outlook: Sustaining Innovation

Wockhardt's pipeline includes more anti-infectives, but academia-pharma synergies are key. Programs at IIT Delhi, IISc Bangalore, and NIPERs train experts in drug discovery. With AMR deaths projected to rise without new drugs, Zaynich heralds hope, potentially positioning India as a global AMR leader.

Stakeholders urge investment in R&D, with calls for tax incentives and university grants to nurture breakthroughs.